PCCA has announced that SuspendIt, one of its proprietary compounding bases, has received verification from the U.S. Pharmacopeia (USP). This marks the third PCCA base to be verified under the USP Ingredient Verification Program for Excipients, following LoxOral and Anhydrous SuspendIt earlier this year.
Gus Bassani, PharmD, CEO of PCCA, stated: “This verification demonstrates our continued commitment to our ‘Quality without Compromise’ core value. Confirmation of quality through independent verification reinforces our promise to pharmacies and patients to deliver purity and consistency with our products. Our goal is to help our members compound with confidence.”
SuspendIt is an all-in-one aqueous compounding base developed for oral suspension formulations. According to PCCA, it allows rapid redispersion of active pharmaceutical ingredients (APIs) with minimal agitation and helps reduce sedimentation for consistent dosing. The product does not contain gluten, alcohol, parabens or dyes.
Bassani added: “We are investing our time and efforts into completing the USP Verification process to verify the quality of our bases, even though regulations do not require it. We plan to continue pursuing this verification for additional PCCA proprietary bases.”
The company reports ongoing investment in research and development aimed at creating patented bases that support personalized medicine and improved therapeutic outcomes. PCCA serves more than 3,000 pharmacy members in multiple countries including the United States, Canada and Australia.
Founded in 1981 by pharmacists, PCCA provides pharmaceutical ingredients as well as education and support services for independent compounding pharmacies worldwide.
Alerts Sign-up